MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio
Shots:
- Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease
- The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders
- AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene- currently in P-II for Parkinson’s Disease and has also received FTD from the US FDA
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
